What does the future of dermatology look like? Vienna-based Scarletred is leading the way with its innovative diagnostic technology. The company is the worldwide leader in standardized skin imaging and AI powered objective skin analysis and was recently featured in Forbes.
Scarletred’s approach leverages proprietary algorithms and a patented skin patch that enables objective measurement of skin changes – from subtle redness to complex dermatological conditions. This allows doctors, pharmaceutical companies, and cosmetic brands to monitor treatment progress and develop new products faster, reducing risk and cutting research costs by up to 50%.
From early research on radiotherapy side effects to building a global SaaS platform, Scarletred has consistently focused on creating real social impact. Their database encompasses a wide range of skin conditions, and the system operates seamlessly on mobile devices, delivering precise measurements under any lighting or equipment conditions.
In 2017, Scarletred was the first company to receive the Austrian State Prize in the category of digitalization. “We are a digital pioneer—and I am proud of that,” said CEO & Founder Harald Schnidar.
Schnidar compared Scarletred’s technology to a thermometer, except that “instead of measuring body temperature, we measure changes in the skin.”
“We want to analyze the problems where they are acute and where other technologies fail,” said Schnidar.
Founded 11 years ago, the company is growing globally. In 2018, Schnidar founded a second branch of Scarletred Inc. in Cambridge, Massachusetts, which he describes as the “Silicon Valley of bio and medtech.” The US location acts as a general importer, which facilitates the delivery of the skin patch and projects with business partners in the US.
Scarletred was also featured at the 2025 World Expo in Osaka, Japan. The company plans to establish a physical branch in Japan by early 2026, as Europe, the US, and Japan are the Scarletred’s main target markets.
Arora®, Scarletred’s new AI agent, represents a major leap forward. It detects complex patterns even in small datasets, supports rare disease analysis, and enhances medical decision-making. By providing actionable insights, Arora® accelerates drug development, improves telemedicine applications, and unlocks new possibilities in skincare innovation.
“Our goal is clear: with our new AI agent Arora®, we will become the ChatGPT of dermatology,” said Schnidar.
